Financial Snapshot

Revenue
$1.722B
TTM
Gross Margin
32.41%
TTM
Net Earnings
-$1.872B
TTM
Current Assets
Q2 2024
Current Liabilities
Q2 2024
Current Ratio
342.78%
Q2 2024
Total Assets
Q2 2024
Total Liabilities
Q2 2024
Book Value
$1.049B
Q2 2024
Cash
Q2 2024
P/E
-0.0007389
Nov 14, 2023 EST
Free Cash Flow
$161.1M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $1.383 Million

About Mallinckrodt plc

Mallinckrodt Plc engages in the development, manufacture, market, adn distribution of both branded and generic specialty pharmaceutical products and medical imaging agents. The firm operates in two reportable segments: Specialty Brands and Specialty Generics. The Specialty Brands includes specialty pharmaceutical brands. The Specialty Generics includes niche specialty generic drugs and active pharmaceutical ingredients. Its Specialty Generics segment is focused on providing its customers with specialty generic drugs and active pharmaceutical ingredients (APIs). The firm focuses on various therapeutic areas, such as autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics, cultured skin substitutes and gastrointestinal products. Its product portfolio includes Acthar Gel, INOmax, Therakos photopheresis, StrataGraft, Terlivaz, and Amitiza.

Industry: Pharmaceutical Preparations Peers: Avadel Pharmaceuticals PLC Endo International plc GH Research PLC Iterum Therapeutics PLC Jazz Pharmaceuticals PLC Nabriva Therapeutics plc Perrigo Company PLC